Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 19, 2017 08:30 ET | Source: UroGen Pharma

Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan

RA’ANANA, Israel, and NEW YORK, July 19, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
June 02, 2017 08:00 ET | Source: UroGen Pharma

UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell

RA’ANANA, Israel and NEW YORK, June 02, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address...
May 30, 2017 08:00 ET | Source: UroGen Pharma

UroGen Pharma to Present at the Jefferies 2017 Global Healthcare Conference

RA’ANANA, Israel and NEW YORK, May 30, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address...
May 16, 2017 08:15 ET | Source: UroGen Pharma

UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors

RA’ANANA, Israel and NEW YORK, May 16, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address...
May 11, 2017 08:00 ET | Source: UroGen Pharma

UroGen Pharma Announces Two Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association 2017 Annual Meeting

RA’ANANA, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in...
May 10, 2017 08:00 ET | Source: UroGen Pharma

UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option

RA’ANANA, Israel and NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address...
May 03, 2017 17:54 ET | Source: UroGen Pharma

UroGen Pharma Announces Pricing of Initial Public Offering

RA’ANANA, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of...
April 24, 2017 07:00 ET | Source: UroGen Pharma

UroGen Pharma Welcomes New Board Member Kate Falberg

RA’ANANA, Israel, April 24, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company that is developing advanced non-surgical treatments to address...
April 03, 2017 08:00 ET | Source: UroGen Pharma

UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma

RA’ANANA, Israel and NEW YORK, April 03, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a privately held, clinical-stage biopharmaceutical company that is developing advanced non-surgical treatments...
December 12, 2016 07:00 ET | Source: UroGen Pharma

UroGen Pharma Announces FDA Acceptance of Investigational New Drug Application for MitoGel, a Novel Sustained Release Formulation of Mitomycin C, for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma

RA’ANANA, Israel and NEW YORK, Dec. 12, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company, today announced the acceptance of its Investigational...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right